AIM ImmunoTech Inc. (AIM)
| Previous Close | 0.4200 |
| Open | 0.4200 |
| Bid | 0.4311 x 1200 |
| Ask | 0.4400 x 1300 |
| Day's Range | 0.4200 - 0.4599 |
| 52 Week Range | 0.3200 - 0.7500 |
| Volume | |
| Avg. Volume | 238,042 |
| Market Cap | 22.28M |
| Beta (5Y Monthly) | -0.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6000 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireAIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production
- GlobeNewswire
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Next safety cohort to begin escalated dosing soonOCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has taken an essential step forward in testing the combination of AIM’s Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (the “DURIPANC” study). See: ClinicalTrials.gov NCT05927142. Investigators at Erasmus Me
- GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, gave an overview of Metastatic Pancreatic Cancer and the ongoing Phase 1b/2 clinical trial combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab
